233 related articles for article (PubMed ID: 22267470)
1. Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Lada O; Gervais A; Branger M; Peytavin G; Roquebert B; Collin G; Fraqueiro G; Moucari R; Leclerc L; Martinot-Peignoux M; Matheron S; Marcellin P
Antivir Ther; 2012; 17(1):61-70. PubMed ID: 22267470
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Lada O; Gervais A; Branger M; Peytavin G; Roquebert B; Collin G; Fraqueiro G; Moucari R; Hamet G; Martinot-Peignoux M; Matheron S; Marcellin P
Liver Int; 2012 Jan; 32(1):93-101. PubMed ID: 22097898
[TBL] [Abstract][Full Text] [Related]
4. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
[TBL] [Abstract][Full Text] [Related]
6. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
[TBL] [Abstract][Full Text] [Related]
7. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
[TBL] [Abstract][Full Text] [Related]
8. Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Karatayli E; Idilman R; Karatayli SC; Cevik E; Yakut M; Seven G; Kabaçam G; Bozdayi AM; Yurdaydin C
Antivir Ther; 2013; 18(1):77-85. PubMed ID: 22878399
[TBL] [Abstract][Full Text] [Related]
9. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
[TBL] [Abstract][Full Text] [Related]
10. Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Mikulska M; Taramasso L; Giacobbe DR; Caligiuri P; Bruzzone B; Di Biagio A; Viscoli C
J Med Virol; 2012 Sep; 84(9):1340-3. PubMed ID: 22825811
[TBL] [Abstract][Full Text] [Related]
11. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
van Bömmel F; Wünsche T; Mauss S; Reinke P; Bergk A; Schürmann D; Wiedenmann B; Berg T
Hepatology; 2004 Dec; 40(6):1421-5. PubMed ID: 15565615
[TBL] [Abstract][Full Text] [Related]
12. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
[TBL] [Abstract][Full Text] [Related]
13. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
[TBL] [Abstract][Full Text] [Related]
14. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
[TBL] [Abstract][Full Text] [Related]
15. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B.
Plaza Z; Aguilera A; Mena A; Vispo E; Sierra-Enguita R; Tomé S; Pedreira J; Rodriguez C; Barreiro P; del Romero J; Soriano V; Poveda E
AIDS; 2013 Sep; 27(14):2219-24. PubMed ID: 23669158
[TBL] [Abstract][Full Text] [Related]
16. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Sheldon J; Camino N; Rodés B; Bartholomeusz A; Kuiper M; Tacke F; Núñez M; Mauss S; Lutz T; Klausen G; Locarnini S; Soriano V
Antivir Ther; 2005; 10(6):727-34. PubMed ID: 16218172
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
[TBL] [Abstract][Full Text] [Related]
18. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations.
Zhu Y; Curtis M; Borroto-Esoda K
Antivir Chem Chemother; 2011 Aug; 22(1):13-22. PubMed ID: 21860069
[TBL] [Abstract][Full Text] [Related]
19. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Salpini R; Alteri C; Cento V; Pollicita M; Micheli V; Gubertini G; De Sanctis GM; Visca M; Romano S; Sarrecchia C; Andreoni M; Angelico M; Parruti G; Svicher V; Perno CF
J Med Virol; 2013 Jun; 85(6):996-1004. PubMed ID: 23588725
[TBL] [Abstract][Full Text] [Related]
20. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]